Forgot your password ?

 login: 

  Why you need to be registered

 password: 

 Register 

Current issueArchivesubscribeInstructions to Authors

search by
Google





subscribe on the news  

 

Pay Color Illustration
 


Medline

PubMed, a service of the National Library of Medicine

World Oncology Network

R.E.Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology



Vol. 28, No. 3, 2006 (October)

Content

UPPER EXTREMITY DVT IN ONCOLOGICAL PATIENTS: ANALYSIS OF RISK FACTORS. DATA FROM THE RIETE REGISTRY

 

M. Monreal1, *, F.J. Munoz2, V. Rosa3, C. Romero4, P. Roman5, P. Di Micco6, P. Prandoni7

1Internal Medicine Division, Hospital of Germans Trias i Pujol University, Badalona, Spain
2Internal Medicine Division, Hospital de Mollet, Barcelona, Spain
3Internal Medicine Division, Hospital Vega Baja, Orihuela, Alicante, Spain
4Internal Medicine Division, Hospital Costa del Sol, Marbella, Malaga, Spain
5Internal Medicine Division, General Hospital of Requena, Requena, Valencia, Spain
6Internal Medicine Division, Buonconsiglio Fatebenefratelli Hospital, Naples, Italy
7Medical and Surgical Science, Medical Clinic II, University of Padova, Padova, Italy

Abstract. Aim: The aim of the study is to up date informations on the clinical characteristics and outcome of patients with upper-extremity deep vein thrombosis (DVT) from the Informatised Registry on Venous Thromboembolism (RIETE). Methods: RIETE is an ongoing registry of consecutive patients with symptomatic, objectively confirmed, acute venous thromboembolism. In this analysis the clinical characteristics and 3-month outcome of all cancer patients with upper-extremity DVT were evaluated. Results: Up to February 2006, a total of 14,391 patients with symptomatic, objectively confirmed acute venous thromboembolism had been enrolled in RIETE. Of the 2,945 patients with active cancer 196 (6.7%) had arm DVT: 104 had catheter-associated DVT. Most cancer patients with arm DVT were males, younger than 65, and had a low incidence of additional risk factors or underlying diseases. Twenty of them (10%) had symptomatic pulmonary embolism (PE). Most patients were treated with low-molecular-weigh heparin, both initially (94%) and after discharge (75%). During the 3-month follow-up period 12 patients (6.1%) developed VTE recurrences (PE 6, DVT 6), 8 (4.1%) had major bleeding (fatal in 3), 43 (22%) died. Conclusions: Our data from the RIETE registry show that upper limb DVT is a serious complication in patients with cancer, with a high incidence of recurrences and bleeding complications.

Key Words: cancer, catheter, vein, thrombosis, risk factor

Language:  English

[full text]




Copyright (c) MORION 1999-2008

Current issue | Archive | subscribe | Instructions to Authors | E-Mail to webmaster